[1] Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health Organization. License: CC BY-NC-SA 30 IGO, 2021.
[2] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol , 2018, 3(6): 383-403.
[3] 尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版). 实用肝脏病杂志. 2023: 457-478.
[4] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut, 2015, 64(12): 1972-1984.
[5] Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife, 2012, 3.
[6] Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res, 2020, 180: 104824.
[7] Wei L, Ploss A. Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nat Microbiol, 2020, 5(5): 715-726.
[8] Wei L, Ploss A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand. Nat Commun, 2021, 12(1): 1591.
[9] Zoulim F, Testoni B. Eliminating cccDNA to cure hepatitis B virus infection. J Hepatol, 2023, 78(4): 677-680.
[10] Seeger C, Sohn JA. Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids, 2014, 3(12): e216.
[11] Wang L, Zhu Q, Zhang JD, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol, 2023, 78(4): 742-753.
[12] Hong X, Kim ES, Guo H. Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. Hepatology, 2017, 66(6): 2066-2077.
[13] 陈娟, 黄爱龙. 从HBV cccDNA角度谈乙型肝炎的功能性治愈. 临床肝胆病杂志, 2022, 38(08): 1716-1720.
[14] Wei ZQ, Zhang YH, Ke CZ, et al. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation. World J Gastroenterol, 2017, 23(34): 6252-6260.
[15] Decorsière A, Mueller H, van Breugel PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature, 2016, 531(7594): 386-389.
[16] Cheng ST, Hu JL, Ren JH, et al. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx. J Hepatol, 2021, 74(3): 522-534.
[17] Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov, 2019, 18(11): 827-844.
[18] Huang Q, Zhou B, Cai D, et al. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients. Hepatology, 2021, 73(1): 41-52.
[19] Tsiang M, Gibbs CS. Analysis of hepatitis B virus dynamics and its impact on antiviral development. Methods Mol Med, 2004, 96: 361-377.
[20] Tang Y, Liang H, Zeng G, et al. Advances in new antivirals for chronic hepatitis B. Chin Med J (Engl),2022, 135(5): 571-583. |
